Zobrazeno 1 - 10 of 67 pro vyhledávání: '"Suman, Wason"'
1
Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain
Autor: Guanglin Luo, Ling Chen, Walter A. Kostich, Brian Hamman, Jason Allen, Amy Easton, Clotilde Bourin, Michael Gulianello, Jonathan Lippy, Susheel Nara, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Prasadrao Jalagam, Sreenivasulu Naidu Pattipati, Kumaran Dandapani, Manoj Dokania, Pradeep Vattikundala, Vivek Sharma, Saravanan Elavazhagan, Manoj Kumar Verma, Manish Lal Das, Santosh Wagh, Anand Balakrishnan, Benjamin M. Johnson, Kenneth S. Santone, George Thalody, Rex Denton, Hariharan Saminathan, Vinay K. Holenarsipur, Anoop Kumar, Abhijith Rao, Siva Prasad Putlur, Sarat Kumar Sarvasiddhi, Ganesh Shankar, Justin V. Louis, Manjunath Ramarao, Charles M. Conway, Yu-Wen Li, Rick Pieschl, Yuan Tian, Yang Hong, Jonathan Ditta, Arvind Mathur, Jianqing Li, Daniel Smith, Joseph Pawluczyk, Dawn Sun, Shiuhang Yip, Dauh-Rurng Wu, Muthalagu Vetrichelvan, Anuradha Gupta, Alan Wilson, Suma Gopinathan, Suman Wason, Linda Bristow, Charles F. Albright, Joanne J. Bronson, John E. Macor, Carolyn D. Dzierba
Publikováno v: Journal of Medicinal Chemistry. 65:4457-4480
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::38224dcaf3d9ea2fabc4ac6df4a42a84
https://doi.org/10.1021/acs.jmedchem.1c02131
Zobrazit plný text záznamu
2
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients with Type 2 Diabetes: a Randomized, Double-Blind Study
Autor: Maximilian G. Posch, Niklas Walther, Ele Ferrannini, David R. Powell, Phillip Banks, Suman Wason, Raphael Dahmen
OBJECTIVE Inhibiting sodium–glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235ca9e0759259295320417f21733282
https://doi.org/10.2337/figshare.20069063.v1
Zobrazit plný text záznamu
3
Discovery of (
Autor: Guanglin, Luo, Ling, Chen, Walter A, Kostich, Brian, Hamman, Jason, Allen, Amy, Easton, Clotilde, Bourin, Michael, Gulianello, Jonathan, Lippy, Susheel, Nara, Tarun Kumar, Maishal, Kamalraj, Thiyagarajan, Prasadrao, Jalagam, Sreenivasulu Naidu, Pattipati, Kumaran, Dandapani, Manoj, Dokania, Pradeep, Vattikundala, Vivek, Sharma, Saravanan, Elavazhagan, Manoj Kumar, Verma, Manish Lal, Das, Santosh, Wagh, Anand, Balakrishnan, Benjamin M, Johnson, Kenneth S, Santone, George, Thalody, Rex, Denton, Hariharan, Saminathan, Vinay K, Holenarsipur, Anoop, Kumar, Abhijith, Rao, Siva Prasad, Putlur, Sarat Kumar, Sarvasiddhi, Ganesh, Shankar, Justin V, Louis, Manjunath, Ramarao, Charles M, Conway, Yu-Wen, Li, Rick, Pieschl, Yuan, Tian, Yang, Hong, Jonathan, Ditta, Arvind, Mathur, Jianqing, Li, Daniel, Smith, Joseph, Pawluczyk, Dawn, Sun, Shiuhang, Yip, Dauh-Rurng, Wu, Muthalagu, Vetrichelvan, Anuradha, Gupta, Alan, Wilson, Suma, Gopinathan, Suman, Wason, Linda, Bristow, Charles F, Albright, Joanne J, Bronson, John E, Macor, Carolyn D, Dzierba
Publikováno v: Journal of medicinal chemistry. 65(6)
Recent mouse knockout studies identified adapter protein-2 associated kinase 1 (AAK1) as a viable target for treating neuropathic pain. Potent small-molecule inhibitors of AAK1 have been identified and show efficacy in various rodent pain models. (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1e41976413f9c4afd18a0630ac9bd2a0
https://pubmed.ncbi.nlm.nih.gov/35257579
Zobrazit plný text záznamu
4
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
Autor: Darren K. McGuire, Mark O'Neill, Frank Mikell, Anne L. Peters, Claire Baker, Phillip Banks, Diane Gesty‐Palmer, Suman Wason, Thomas Danne, Sangeeta Sawhney, Paul Strumph, Anna Chang, Jake A. Kushner
Publikováno v: Diabetes, Obesity & Metabolism
Aims To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D). Materials and methods In this 12‐week, multicentre, randomized, double‐blind, placebo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e569d763c211bd8fce1076a7a1ad43ea
https://doi.org/10.1111/dom.13825
Zobrazit plný text záznamu
5
Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants
Autor: Thomas L. Hunt, LuAnn Bundrant, Alan Wilson, Kenneth Kassler-Taub, Chris Warner, Phil Banks, Praveen Tyle, Suma Gopinathan, Suman Wason, Kristi A. Boehm
Publikováno v: Clinical therapeutics. 43(6)
Purpose For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a new small-molecule AP2-associated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a718db9c0cb48300a58b7740a2bfe9e
https://pubmed.ncbi.nlm.nih.gov/34108079
Zobrazit plný text záznamu
8
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Autor: Wenjun Jiang, Richard R.P. Warner, Petros Perros, Raj Srirajaskanthan, Lowell Anthony, Rosanna Fleming, Matthew H. Kulke, Dieter Hörsch, Suman Wason, David J. Gross, Douglas Fleming, Martin O. Weickert, Pamela L. Kunz, Rocio Garcia-Carbonero, Marta Benavent, Marianne Pavel, Pablo Lapuerta, Kenneth Kassler-Taub
Publikováno v: Endocrine-Related Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bf32ab23bda5252d3ddf51cce13710
https://pubmed.ncbi.nlm.nih.gov/29330194
Zobrazit plný text záznamu
9
Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
Autor: Suman Wason, David B. Mount, Robert Faulkner
Publikováno v: Clinical Drug Investigation. 34:845-855
The effect of renal impairment on colchicine pharmacokinetics in patients with chronic kidney disease (CKD) has not been studied previously. We evaluated the effect of renal impairment on colchicine pharmacokinetics in patients with CKD. The pharmaco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ce9f19df5d266b30d0ef601306284e
https://doi.org/10.1007/s40261-014-0238-6
Zobrazit plný text záznamu
10
Colchicine-Antimicrobial Drug Interactions: What Pharmacists Need to Know in Treating Gout
Autor: Jennifer L. DiGiacinto, Suman Wason, Matthew W. Davis
Publikováno v: The Consultant Pharmacist. 28:176-183
Objective Review the magnitude and clinical relevance of drug-drug interactions between a new formulation of colchicine, used to treat gout, and antibiotics. SETTING AND PRACTICE DESCRIPTION: Relevant to community and institutional pharmacists servic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14540bb525b6395afc1827fa376d0347
https://doi.org/10.4140/tcp.n.2013.176
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje